Milvexian's Phase 3 Readout: BMS's Binary Bet on an Unproven Mechanism Against a Proven Standard

BMS Faces Critical Milvexian Trial Readout Amid Patent Cliff

Bristol Myers Squibb (BMS) is approaching a critical juncture with the upcoming readout of its Phase 3 LIBREXIA AF trial for the oral FXIa inhibitor milvexian. Analysts warn that a failure could lead to significant financial challenges, including a 40-50% drop in share price, due to an impending patent cliff affecting major revenue drivers like Eliquis and Opdivo by 2031. This situation could trigger consolidation among large-cap drugmakers, with BMS potentially becoming a takeover target. The company's future growth hinges on milvexian's success, as current pipeline assets may not fully offset projected revenue losses.

• The success of milvexian in the Phase 3 LIBREXIA AF trial for atrial fibrillation is deemed binary for BMS's future. This is critical given previous failures of the LIBREXIA ACS program and setbacks in stroke, as well as the failure of Bayer's rival FXIa inhibitor, asundexian. Analysts estimate milvexian's success chance in atrial fibrillation at 60%.
• BMS faces a severe patent cliff, with approximately 80% of its revenue base vulnerable to generic or biosimilar competition by 2031. Key drugs Eliquis and Opdivo are expected to lose exclusivity by late 2026 and 2028, respectively, with Eliquis's entire revenue base potentially erased by 2030, creating a significant revenue void.
• While BMS has other promising assets like the LPA1 antagonist admilparant for pulmonary fibrosis, and established products like Camzyos and Breyanzi, their potential may not fully compensate for milvexian's failure. A negative outcome could lead to a 'feeding frenzy' among large-cap drugmakers, potentially making BMS, GSK, and Pfizer targets for consolidation.

Understanding the High-Stakes LIBREXIA AF Trial Design

Several key atrial fibrillation (AF) trials span a range of clinical questions — from surgical ablation and anticoagulation timing to remote screening and thrombus resolution — each employing distinct study designs and endpoint frameworks. The table below consolidates the core design parameters and endpoints reported across these trials.

Why Milvexian is Critical for BMS's Future Growth

Recent literature highlights several high-priority unmet needs and underserved populations in atrial fibrillation (AF) management, spanning stroke prevention, cognitive outcomes, and comorbid complexity. The evidence points to a convergence of mechanical, pharmacological, and integrated care strategies aimed at populations where current standard-of-care anticoagulation remains insufficient.

• Patients with AF who experience thromboembolic events despite oral anticoagulation (OAT): This population carries a very high risk of stroke recurrence, and continued OAT alone has demonstrated inadequate protection. A propensity score-matched cohort study found an annualized ischemic stroke event rate of 8.9% per patient-year in patients continuing OAT alone following a prior thromboembolic event on anticoagulation, underscoring a critical gap in secondary stroke prevention for this group.

• Patients requiring stroke prevention strategies beyond anticoagulation — left atrial appendage occlusion (LAAO): Percutaneous LAAO has emerged as a mechanical stroke prevention strategy for AF patients with inadequate response to OAT. In the STR-OAC LAAO cohort, LAAO was associated with a lower risk of ischemic stroke compared with continued OAT alone (hazard ratio, 0.33; 95% CI, 0.19–0.58; P < .001). Case series further illustrate individualized use of LAAO alongside OAC in patients with recurrent thrombo-embolic events, with randomized controlled trial data identified as a key evidence gap.

• Patients at risk of bleeding complications on current anticoagulants: Direct oral anticoagulants carry a dose-dependent increased bleeding risk, which limits their use in certain populations. Milvexian, an oral factor XIa inhibitor, has been identified as a potential agent to provide anticoagulant effect without increased bleeding compared with current standard of care, with phase III trials planned to examine its efficacy in patients with acute stroke, acute coronary syndrome, and AF.

• AF patients with cognitive decline and dementia risk: AF patients face an approximate 1.5-fold increased risk of cognitive decline compared with the general population, rising to an estimated threefold increase among post-stroke AF patients. Oral anticoagulation for stroke prevention is described as one of the only proven therapies to prevent brain injury in this context, yet whether broader or more intense anticoagulation use is beneficial remains an open question requiring future study.

• AF patients with concomitant heart failure (HF): Patients with AF and HF carry a high risk of major adverse events, with the highest figures observed for HF with reduced ejection fraction (hazard ratio, 2.36; 95% CI, 2.00–2.78) compared with no HF. Adherence to optimal medical therapy and the Atrial Fibrillation Better Care pathway was associated with reduced risk of the composite of all-cause death and major adverse cardiovascular events across the spectrum of left ventricular ejection fraction.

• Patients with AF and prior intracranial hemorrhage (ICH): Evidence on initiating OAC in this population has historically been limited. A meta-analysis of 9,181 patients found that OAC therapy significantly reduced ischemic stroke (RR: 0.38; 95% CI: 0.26–0.55; P < 0.00001) and all-cause mortality (RR: 0.68; 95% CI: 0.57–0.81; P < 0.0001) without a significant increase in ICH recurrence (RR: 1.21; 95% CI: 0.69–2.13; P = 0.50), though prospective studies are identified as needed to further refine decision-making in this group.

• Patients with device-detected subclinical AF (SCAF) and atrial high-rate episodes (AHRE): These episodes are associated with a higher risk of clinical AF, stroke, and heart failure, yet optimal thresholds for initiating anticoagulation or rhythm control — particularly for AHRE shorter than 24 hours — remain undefined. Further prospective studies are identified as needed to define risk thresholds that justify intensified rhythm surveillance and early intervention in this population.

Navigating the Competitive Landscape for Oral FXIa Inhibitors

Milvexian belongs to the class of oral factor XIa (FXIa) inhibitors, a mechanism shared by several other agents currently under clinical investigation for stroke prevention in atrial fibrillation (AF) and related thromboembolic indications. The trials evaluating these agents have employed a range of intervention models, from placebo-controlled dose-finding studies to active-comparator designs against established direct oral anticoagulants (DOACs).

The knowledge base does not have sufficient information on this aspect. Specifically, the intervention model details for osocimab, fesomersen, and xisomab 3G3 trials are not reported in the available literature, nor are the specific trial names for these agents beyond what is noted above.

Milvexian's Make-or-Break Moment for BMS

The pharmaceutical industry is keenly awaiting the results of the LIBREXIA AF trial, a moment that could redefine the trajectory for Bristol Myers Squibb. With a significant patent cliff looming for blockbuster drugs like Eliquis and Opdivo, the success of milvexian, an oral Factor XIa inhibitor, is not merely a pipeline win but a critical determinant of the company's future financial health and independence. The stakes are exceptionally high, with analysts forecasting severe financial repercussions, including a substantial share price decline and potential M&A activity, should the trial fail.

Milvexian enters a market currently dominated by direct oral anticoagulants (DOACs) such as apixaban, which have demonstrated robust efficacy and safety in preventing stroke in patients with atrial fibrillation, with established dosing strategies to manage individual patient risks. The LIBREXIA AF trial is designed to assess if milvexian is noninferior to apixaban in preventing stroke and systemic embolism, while simultaneously aiming for superiority in reducing major bleeding events. This dual objective presents a considerable challenge.

Several factors contribute to the inherent risks. The noninferiority bar against a highly effective and well-tolerated drug like apixaban is demanding. Furthermore, while the promise of Factor XIa inhibition lies in potentially uncoupling antithrombotic efficacy from bleeding risk, prior model-informed dose selection for milvexian in atrial fibrillation indicated no clear relationship between drug exposure and bleeding in earlier studies. This suggests that demonstrating a statistically significant reduction in bleeding events, a key differentiator for milvexian, may prove difficult. The backdrop of a Phase 2 trial (AXIOMATIC-SSP) in secondary stroke prevention, which did not show a substantial reduction in ischemic events, further underscores the pressure on the LIBREXIA AF results. A positive outcome would not only secure a vital revenue stream but also validate a novel anticoagulant class, potentially offering a safer option for patients currently underserved due to bleeding concerns. Conversely, a negative readout would necessitate a rapid re-evaluation of the company's strategic pipeline and could trigger significant corporate restructuring.